losartan has been researched along with Hyperlipemia in 14 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| " MASSIVE PROTEINURIA: An angiotensin II inhibitor, losartan, has been found to be effective against massive proteinuria (> 3." | 3.71 | [Complications in kidney transplantation]. ( Ouali, N, 2001) |
| " It has been proposed that the elevated serum uric acid levels are linked to other risk factors, such as hypertension, dyslipidaemia and diabetes." | 3.70 | Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. ( Elisaf, MS; Milionis, HJ, 2000) |
| "Hemodialysis patients have uremic dyslipidemia, represented by elevated serum intermediate-density lipoprotein cholesterol (IDL-C) levels, and an increased cardiovascular mortality rate." | 2.71 | Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. ( Furukawa, T; Hayashi, M; Homma, K; Ichihara, A; Kaneshiro, Y; Kanno, Y; Saruta, T; Takemitsu, T; Takenaka, T; Yoshizawa, M, 2005) |
| "Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important." | 2.44 | [Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008) |
| "We investigated the effects of co-administration of an angiotensin-converting enzyme inhibitor (ACEI) and angiotensin type 1 receptor blocker (ARB) on nitric oxide (NO) bioavailability in genetically hyperlipidemic rabbits with our newly developed NO sensor." | 1.35 | Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits. ( Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Yoshida, K, 2008) |
| "Captopril was more effective than losartan in preserving of nitric oxide." | 1.34 | [Comparative characteristic of angiotensin-converting enzyme inhibitor--captopril and the angiotensin II receptor blokers--losartan action on the oxidative metabolism in experimental hyperlipidemia in rabbits]. ( Antelava, NA; Gogolauri, MI; Gongadze, NV; Kezeli, TD; Pachkoriia, KZ, 2007) |
| " Group 2 (n = 5) was treated with enalapril at a dosage of 50 mg/l in drinking water starting at 6 weeks of age." | 1.29 | Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. ( Baba, N; Sakemi, T, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 11 (78.57) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Elseweidy, MM | 1 |
| Elnagar, GM | 1 |
| M Elsawy, M | 1 |
| Ali, AA | 1 |
| Zein, N | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Yang, H | 1 |
| Narita, I | 1 |
| Kon, V | 1 |
| Chan, EC | 1 |
| Jones, GT | 1 |
| Dusting, GJ | 1 |
| Datla, SR | 1 |
| Jiang, F | 1 |
| Diener, HC | 1 |
| el-Batran, SA | 1 |
| el-Shenawy, SM | 1 |
| Nofal, SM | 1 |
| Abdel-Salam, OM | 1 |
| Arbid, MS | 1 |
| Ichihara, A | 1 |
| Hayashi, M | 1 |
| Kaneshiro, Y | 1 |
| Takemitsu, T | 1 |
| Homma, K | 1 |
| Kanno, Y | 1 |
| Yoshizawa, M | 1 |
| Furukawa, T | 1 |
| Takenaka, T | 1 |
| Saruta, T | 1 |
| Vogt, L | 1 |
| Laverman, GD | 1 |
| van Tol, A | 1 |
| Groen, AK | 1 |
| Navis, G | 1 |
| Dullaart, RP | 1 |
| Antelava, NA | 1 |
| Gongadze, NV | 1 |
| Gogolauri, MI | 1 |
| Kezeli, TD | 1 |
| Pachkoriia, KZ | 1 |
| Ogino, K | 1 |
| Igawa, O | 1 |
| Hisatome, I | 1 |
| Imanishi, T | 1 |
| Kuroi, A | 1 |
| Ikejima, H | 1 |
| Kobayashi, K | 1 |
| Muragaki, Y | 1 |
| Mochizuki, S | 1 |
| Goto, M | 1 |
| Yoshida, K | 1 |
| Akasaka, T | 1 |
| Sakemi, T | 1 |
| Baba, N | 1 |
| Milionis, HJ | 1 |
| Elisaf, MS | 1 |
| Chen, HJ | 1 |
| Li, DY | 1 |
| Saldeen, T | 1 |
| Phillips, MI | 1 |
| Mehta, JL | 1 |
| Ouali, N | 1 |
1 review available for losartan and Hyperlipemia
| Article | Year |
|---|---|
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout | 2008 |
1 trial available for losartan and Hyperlipemia
| Article | Year |
|---|---|
Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blo | 2005 |
12 other studies available for losartan and Hyperlipemia
| Article | Year |
|---|---|
Losartan and azelastine either alone or in combination as modulators for endothelial dysfunction and platelets activation in diabetic hyperlipidemic rats.
Topics: Alloxan; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Blood Platelets; Diabete | 2020 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Prevention of aortic elastic lamina defects by losartan in apolipoprotein(E)-deficient mouse.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseas | 2009 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats.
Topics: Alloxan; Animals; Blood Glucose; Blood Proteins; Carbamates; Cholesterol, LDL; Diabetes Mellitus, Ex | 2004 |
Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment.
Topics: Adult; Analysis of Variance; Apolipoproteins; Biological Transport; Case-Control Studies; Cholestero | 2006 |
[Comparative characteristic of angiotensin-converting enzyme inhibitor--captopril and the angiotensin II receptor blokers--losartan action on the oxidative metabolism in experimental hyperlipidemia in rabbits].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri | 2007 |
Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; An | 2008 |
Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; | 1993 |
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
Topics: Antihypertensive Agents; Arteriosclerosis; Benzothiadiazines; Diuretics; Female; Fenofibrate; Humans | 2000 |
Attenuation of tissue P-selectin and MCP-1 expression and intimal proliferation by AT(1) receptor blockade in hyperlipidemic rabbits.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Arteriosclerosis; Chemokine CCL2; | 2001 |
[Complications in kidney transplantation].
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Graft Rejection; Humans; H | 2001 |